Accession Number

Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers Label, gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia 2. It is considered a cytoprotective agent, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances 2,13.

Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form 11,12.

Small Molecule
Average: 1558.67
Monoisotopic: 1557.6045961
Chemical Formula
  • Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
  • Sucralfat
  • Sucralfate
  • Sucralfato
  • Sucralfatum
External IDs
  • CGA-6J
  • OS 202


Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more

The sucralfate suspension Label and tablet 15 are used for the treatment of active duodenal ulcer for up to 8 weeks. The tablet form may be used at a lower dose for healed duodenal ulcers, for the purpose of maintaining healing and preventing recurrence 13,15.

Sucralfate is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia 2,13.

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more

This drug aids in the healing of duodenal ulcers, relieving painful inflammation by creating a protective mechanical barrier between the lining or skin of the gastrointestinal tract and damaging substances 2. In addition, sucralfate acts to increase levels of growth factors locally, and also causes an increase in prostaglandins which are important in the healing of the mucosa (lining) of the gastrointestinal tract 2.

Mechanism of action

The mechanism of action of this drug in the healing duodenal ulcers is not yet completely defined, however, there are several probable mechanisms that adequately describe the healing activity of sucralfate. There is evidence that sucralfate acts locally to aid in tissue healing, and not systemically Label.

Studies in both humans and animals have indicated that sucralfate forms a complex that binds to protein-rich exudate found on the surface of ulcers. It binds to albumin and fibrinogen 7,8 preventing blood clot lysis by stomach acid (hydrochloric acid). Sucralfate increases the tissue levels of fibroblast growth factors and epidermal growth factors 6, leading to an increase in prostaglandins at the gastrointestinal tract lining, which promote the healing of gastrointestinal ulcers 2.

In the laboratory setting, a sucralfate-albumin film provides a barrier against the entry of hydrogen ions, which are a component of gastric acid. In humans, sucralfate, given at therapeutic doses for ulcers, decreases pepsin activity in gastric fluids by 32% Label. Pepsin has been shown to be damaging to tissues, further aggravating ulcer lesion inflammation 4. Bile salts have been implicated in mucosal injury to the gastrointestinal tract 9,10. Sucralfate has also been shown to adsorb bile salts in the laboratory, setting, which could further contribute to its beneficial effects in ulcer healing Label.

APepsin A-5
AFibroblast growth factor 2
APro-epidermal growth factor

This drug is absorbed from the gastrointestinal tract in very minimal quantities Label. The adsorbed sulfated disaccharide is excreted in the urine 13. This drug contains aluminum and after the administration of 1 g of sucralfate 4 times per day, about 0.001% to 0.017% of this aluminum content is absorbed in patients with normal renal function 13. This number is expected to increase in those with impaired renal function 13.

Volume of distribution

This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions Label.

Protein binding

Sucralfate is bound to plasma proteins, especially albumin and transferrin 13.


This drug is absorbed in very small quantities and is not significantly metabolized Label,13.

Route of elimination

The negligible amount of this drug that is absorbed is excreted mainly in the urine within 48 hours Label,16.


The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h 16.


Sucralfate contains aluminum. The administration of sucralfate in non-dialyzed chronic renal failure patients warrants careful consideration from the treating physician as the excretion of absorbed aluminum may be decreased, causing possible aluminum toxicity 13.

In dialyzed patients diagnosed with chronic renal failure, aluminum toxicity related to sucralfate has been observed and reported. The daily amount of aluminum ingestion (including sucralfate) should be carefully examined before administering sucralfate in combination with other drugs also containing aluminum, including various antacids 13.

Adverse Effects
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more


Overdosage has never been observed with sucralfate 13. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies 13. It is likely that overdose of sucralfate in humans would result in constipation, and supportive treatment would be advised 13.

Use in pregnancy

This drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women. Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health Label.

Use in nursing

Whether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed Label.


24 month toxicity studies were performed in rodents, and the dose of sucralfate reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of sucralfate-related tumors were notedLabel.

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbacavirSucralfate may decrease the excretion rate of Abacavir which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Sucralfate.
AcetaminophenAcetaminophen may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AclidiniumSucralfate may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineSucralfate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
  • Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.
  • Take separate from antacids. Take at least 30 minutes before or after antacids.


Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Images
International/Other Brands
Antepsin (Orion) / Sucramal (Menarini) / Sucraxol (Medifarma) / Ulcogant (Merck)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CarafateSuspension1 g/10mLOralAtlantic Biologicals Corp.1993-12-16Not applicableUS flag
CarafateSuspension1 g/10mLOralPhysicians Total Care, Inc.1996-03-12Not applicableUS flag
CarafateTablet1 g/1OralAllergan, Inc.1981-10-30Not applicableUS flag
CarafateSuspension1 g/10mLOralAllergan1993-12-16Not applicableUS flag
SucralfateTablet1 g/1OralRemedy Repack2010-05-202010-12-10US flag
SucralfateSuspension1 g/10mLOralPhysicians Total Care, Inc.2005-05-24Not applicableUS flag
SucralfateSuspension1 g/10mLOralVistapharm, Inc.2012-08-16Not applicableUS flag
SucralfateSuspension1 g/10mLOralCardinal Health2009-11-192017-10-31US flag
SucralfateTablet1 g/1OralAphena Pharma Solutions Tennessee, Inc.1996-11-01Not applicableUS flag
SucralfateSuspension1 g/10mLOralCardinal Health2012-08-162018-09-30US flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-sucralfate - Tab 1gTabletOralApotex Corporation1994-12-31Not applicableCanada flag
CarafateTablet1 g/1OralAdvanced Rx Pharmacy of Tennessee, LLC1996-11-11Not applicableUS flag
Dom-sucralfateTabletOralDominion Pharmacal1999-09-152016-10-25Canada flag
Nu-sucralfate - Tab 1gmTabletOralNu Pharm Inc1994-12-312012-09-04Canada flag
PMS-sucralfateTabletOralPharmascience Inc1999-02-23Not applicableCanada flag
SucralfateTablet1 g/1OralPreferred Pharmaceuticals Inc.2015-10-27Not applicableUS flag68788 894620180907 15195 sk7v1d
SucralfateSuspension1 g/10mLOralAtlantic Biologicals Corp.2020-01-27Not applicableUS flag
SucralfateTablet1 g/1OralMc Kesson Contract Packaging1996-11-112017-09-30US flag
SucralfateTablet1 g/1OralAv Kare, Inc.2014-01-17Not applicableUS flag
SucralfateTablet1 g/1OralPrasco, Laboratories2009-07-012011-01-05US flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
SUCRALTablet500 mgOralบริษัท โอลิค (ประเทศไทย) จำกัด1998-12-04Not applicableThailand flag
ซูคราเฟนTablet1000 mgOralห้างหุ้นส่วนจำกัด โรงงานเลิศสิงห์เภสัชกรรม1995-08-16Not applicableThailand flag
ซูเครทเจลSuspension1000 mg/5mlOralบริษัท นีโอ ฟาร์ม จำกัด จำกัด2007-11-29Not applicableThailand flag
อัลซีเฟต ชนิดยาน้ำแขวนตะกอนSuspension1000 mg/5mlOralบริษัท สยามเภสัช จำกัด1990-08-17Not applicableThailand flag
อัลซีเฟต ชนิดเม็ด (1 กรัม)บริษัท สยามเภสัช จำกัด2019-07-25Not applicableThailand flag
อัลซีเฟต ชนิดเม็ด (500 มก.)Tablet, chewableOralบริษัท สยามเภสัช จำกัด2019-07-25Not applicableThailand flag
อัลซีเฟต ชนิดเม็ดเคี้ยวTablet, chewableOralบริษัท สยามเภสัช จำกัด2009-08-11Not applicableThailand flag


ATC Codes
A02BX02 — Sucralfate
Drug Categories
Not classified

Chemical Identifiers

CAS number
InChI Key
[({[(2R,3R,4S,5R,6R)-6-{[(2S,3S,4R,5R)-3,4-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2,5-bis[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxolan-2-yl]oxy}-4,5-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxan-3-yl]oxy}sulfonyl)oxy]alumanediol alumanetriol hydrate


Synthesis Reference

Nick V. Lazaridis, Moo K. Park, Yousry Sayed, "Method for preparing high potency sucralfate." U.S. Patent US4990610, issued March, 1973.

General References
  1. Rees WD: Mechanisms of gastroduodenal protection by sucralfate. Am J Med. 1991 Aug 8;91(2A):58S-63S. [PubMed:1715673]
  2. Candelli M, Carloni E, Armuzzi A, Cammarota G, Ojetti V, Pignataro G, Santoliquido A, Pola R, Pola E, Gasbarrini G, Gasbarrini A: Role of sucralfate in gastrointestinal diseases. Panminerva Med. 2000 Mar;42(1):55-9. [PubMed:11019606]
  3. Lam SK: Why do ulcers heal with sucralfate? Scand J Gastroenterol Suppl. 1990;173:6-16. [PubMed:2190306]
  4. Bardhan KD, Strugala V, Dettmar PW: Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10. [PubMed:22242022]
  5. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  6. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825]
  7. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
  8. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [PubMed:2612985]
  9. Gadacz TR, Zuidema GD: Bile acid composition in patients with and without symptoms of postoperative refulx gastritis. Am J Surg. 1978 Jan;135(1):48-52. [PubMed:341732]
  10. Duane WC, Wiegand DM: Mechanism by which bile salt disrupts the gastric mucosal barrier in the dog. J Clin Invest. 1980 Nov;66(5):1044-9. doi: 10.1172/JCI109932. [PubMed:7430343]
  11. FDA approval, Sucralfate suspension [Link]
  12. Sucralfate tablet FDA approval [Link]
  13. Product monograph, Sulcrate [File]
  14. MedSafe NZ, Sucralfate [File]
  15. Sucralfate FDA label, tablet form [File]
  16. Risk profile of sucralfate [File]
Human Metabolome Database
KEGG Compound
PubChem Compound
PubChem Substance
RxList Drug Page Drug Page
PDRhealth Drug Page
AHFS Codes
  • 56:28.32 — Protectants
FDA label
Download (217 KB)
Download (73.6 KB)

Clinical Trials

Clinical Trials
4CompletedTreatmentAntimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentChronic Erosive Gastritis1
4CompletedTreatmentChronic Radiation Proctitis1
3CompletedSupportive CareHead and Neck Carcinoma / Mucositis1
2Unknown StatusSupportive CareGingivostomatitis / Hand, Foot and Mouth Disease (HFMD) / Herpangina1
1RecruitingTreatmentNeuroendocrine Tumor GEP Grade 1-3 / Neuroendocrine Tumor of the Lung Grade 1 and 2 / Neuroendocrine Tumor of the Thymus Grade 1 and 2 / Thyroid Cancer, Medullary1
1, 2RecruitingTreatmentType 1 Diabetes Mellitus1
0CompletedTreatmentOesophagitis, Eosinophilic1
Not AvailableRecruitingNot AvailableGastritis, Atrophic1


  • Axcan pharma us inc
  • Nostrum laboratories inc
  • Teva pharmaceuticals usa inc
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • A-S Medication Solutions LLC
  • Axcan Pharma Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Giant Food Inc.
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Ivax Pharmaceuticals
  • Levista Inc.
  • Long Wing International Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Merckle GmbH
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nostrum Laboratories Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Prasco Labs
  • Precision Dose Inc.
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Prime European Therapeuticals SPA
  • Qingdao Pana Life Biochem Co. Ltd.
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sanofi-Aventis Inc.
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Vistapharm Inc.
  • Warrick Pharmaceuticals Corp.
  • Watson Pharmaceuticals
  • Xactdose Inc.
Dosage Forms
Powder, for suspensionOral1 g
Tablet, chewableBuccal500 mg
PowderOral1 G
PowderOral2 G
SuspensionOral20 %
Tablet, solubleOral1000 mg
TabletOral1 g
SuspensionOral1 g/5ml
Tablet, coatedOral100 mg
GelOral1 G
Granule, for suspensionOral1 g
Granule, for suspensionOral2 G
Tablet, chewableOral1 G
Tablet, chewableOral1000 mg
SuspensionOral500 MG/5ML
SuspensionOral500 MG
SuspensionOral2 G/100ML
TabletOral200 MG
SuspensionOral1 g/10mL
TabletOral1 g/1
PowderNot applicable1 kg/1kg
TabletOral1.11 mg
TabletOral500 mg
Powder, for suspensionOral2 G
TabletOral1000 MG
GranuleOral1 g
GelOral1 G/5ML
GelOral2 G/10ML
Granule, for solutionOral1 g
SuspensionOral20 G/100ML
Tablet, coatedOral1000 mg
SuspensionOral20 g
GranuleOral2 G
Tablet, chewableOral2 G
SuspensionOral1000 mg/5ml
Tablet, chewableOral
Unit descriptionCostUnit
Sucralfate 1 gm/10ml Suspension 10ml Cup13.99USD cup
Carafate 1 gm tablet1.45USD tablet
Sucralfate 1 gm tablet0.72USD tablet
Sucralfate powder0.6USD g
Sulcrate 1 g Tablet0.59USD tablet
Apo-Sucralfate 1 g Tablet0.31USD tablet
Novo-Sucralate 1 g Tablet0.31USD tablet
Nu-Sucralfate 1 g Tablet0.31USD tablet
Pms-Sucralfate 1 g Tablet0.31USD tablet
Carafate 1 gm/10ml Suspension0.24USD ml
Sulcrate Suspension Plus 200 mg/ml Suspension0.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Not Available


Experimental Properties
melting point (°C)>220
water solubilityInsoluble
pKa 0.43 to 1.19
Predicted Properties
Water Solubility0.774 mg/mLALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count35ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area772.17 Å2ChemAxon
Rotatable Bond Count37ChemAxon
Refractivity180.03 m3·mol-1ChemAxon
Polarizability107.19 Å3ChemAxon
Number of Rings2ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Human Intestinal Absorption-0.7959
Blood Brain Barrier+0.8803
Caco-2 permeable-0.6433
P-glycoprotein substrateNon-substrate0.8087
P-glycoprotein inhibitor INon-inhibitor0.5656
P-glycoprotein inhibitor IINon-inhibitor0.986
Renal organic cation transporterNon-inhibitor0.8471
CYP450 2C9 substrateNon-substrate0.8611
CYP450 2D6 substrateNon-substrate0.8256
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.772
CYP450 2C9 inhibitorNon-inhibitor0.8211
CYP450 2D6 inhibitorNon-inhibitor0.8865
CYP450 2C19 inhibitorNon-inhibitor0.7869
CYP450 3A4 inhibitorNon-inhibitor0.9828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.5805
BiodegradationNot ready biodegradable0.8432
Rat acute toxicity2.4219 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7937
hERG inhibition (predictor II)Non-inhibitor0.8793
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
Not Available


Pharmacological action
General Function
Shows particularly broad specificity; although bonds involving phenylalanine and leucine are preferred, many others are also cleaved to some extent.
Specific Function
Aspartic-type endopeptidase activity
Gene Name
Uniprot ID
Uniprot Name
Pepsin A-5
Molecular Weight
41992.845 Da
  1. Jensen SL, Funch Jensen P: Role of sucralfate in peptic disease. Dig Dis. 1992;10(3):153-61. [PubMed:1611711]
  2. Hollander D, Tarnawski A: The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1-5. [PubMed:2190304]
  3. Peterson WL: Pathogenesis and therapy of peptic ulcer disease. J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. [PubMed:1978840]
  4. Kegg [Link]
Pharmacological action
General Function
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
Uniprot ID
Uniprot Name
Fibroblast growth factor 2
Molecular Weight
30769.715 Da
  1. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  2. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  3. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M: Growth factors: new 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl. 1995;210:15-8. [PubMed:8578198]
  4. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825]
Pharmacological action
General Function
Transmembrane receptor protein tyrosine kinase activator activity
Specific Function
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in ...
Gene Name
Uniprot ID
Uniprot Name
Pro-epidermal growth factor
Molecular Weight
133993.12 Da
  1. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  2. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  3. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337]
4. Fibrinogen
Pharmacological action
This group includes the fibrinogen alpha chain, beta chain, and gamma chain.
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
  2. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [PubMed:2612985]
  3. Sucralfate - Drug Summary [Link]

Drug created on June 13, 2005 13:24 / Updated on March 04, 2021 11:10